Breaking News

Lilly to Acquire POINT Biopharma in $1.4B Deal

Expands oncology capabilities with next-generation radioligand therapies in development to treat cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. entered a definitive agreement to acquire POINT Biopharma Global, Inc., a radiopharmaceutical company with a pipeline of radioligand therapies in development for the treatment of cancer, for approximately $1.4 billion. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, enabling significant anti-tumor efficacy while limiting the impact to healthy tissue.   POINT&#821...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters